IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

IRVINE, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

PHILADELPHIA — Six-month data from the CLASP study showed a transcatheter mitral valve repair system for patients with functional mitral regurgitation conferred acceptable safety and statistically ...

Hausleiter J. First commercial multicenter experience with the PASCAL transcatheter valve repair system for tricuspid regurgitation. Presented at: TVT 2021. July 21. 2021. Miami, FL. MIAMI, FL—The ...

Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from ...

Progress continues to be made on new transcatheter devices for the treatment of severe mitral and tricuspid regurgitation, investigators reported. Several valve repair and replacement technologies, ...

Edwards Lifesciences has scored a CE mark for its Pascal Precision transcatheter valve repair system for the treatment of mitral and tricuspid regurgitation (MR and TR). "Delivering the Pascal ...

Edwards Lifesciences said expanded use of its Pascal transcatheter valve repair system drove strong sales in the first quarter as an increasing number of heart centers adopt the technology. Meanwhile, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “A minimally invasive, transcatheter leaflet strategy ...

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

The US Food and Drug Administration (FDA) has approved the PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) in patients with degenerative mitral ...